> Zambon completed the acquisition of Breath Therapeutics. The takeover gives Zambon control of a phase 3 treatment for a rare fatal respiratory disease. Release
> Transgene received U.K. regulatory clearance to trial its TG6002 oncolytic virus. Statement
> BiomX secured itself a U.S. stock listing through a deal with Chardan Healthcare Acquisition. Release
> Nasdaq told Motif Bio that it no longer meets the minimum requirements for listing. Motif Bio has until mid-January to regain compliance. Statement
> The AMR Centre struck a deal with Shionogi for anti-virulence program COT-143. The plan is to run clinical trials of the asset next year. Release
> Novo Holdings’ Repair impact fund invested $10 million in Curza and Spero. Statement